You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu

News

Medigene reveals pivotal blood cancer therapy data

Medigene – a company concentrating on the development of T cell immunotherapies for solid tumours – has announced final phase 1 dose-escalation results from the study of its MDG1011 candidate.